Why compare them?
These records are compared to clarify how their mechanisms, research areas, and evidence maturity differ.
Simple first. Deeper when you want it.
Understand the differences that matter.
See the biggest similarities, differences, strengths, limitations, and unanswered questions first—then open the evidence behind them.
Compound comparison
DSIP vs. Tirzepatide
Understand the meaningful overlap, differences, evidence, and unknowns—then go deeper only when you want to.
60-Second Summary
The answer first
Current evidenceComparable evidence base
No direct head-to-head study is represented. This comparison uses separate evidence records that may differ in population, duration, route, dose, and endpoint.
✓ Shared
Shared Similarities
- Both have controlled human research, although the questions and designs may differ.
⇄ Different
Biggest Difference
DSIP is distinguished by dSIP is a sleep-associated nonapeptide whose name overstates the human evidence; old intravenous insomnia studies were tiny and inconsistent, and no FDA-approved formulation or subcutaneous program exists; Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base.
? Unknown
Biggest Unknown
No direct head-to-head study establishes how these compounds compare under the same population, dose, duration, and endpoints.
Key Takeaways
DSIP is distinguished in the current record by dSIP is a sleep-associated nonapeptide whose name overstates the human evidence; old intravenous insomnia studies were tiny and inconsistent, and no FDA-approved formulation or subcutaneous program exists. Tirzepatide is distinguished by dual agonist at GIP and GLP-1 receptors, with approved U.S. products and a much larger completed evidence base. Neither is objectively “better”; the useful question is which evidence record addresses the research question being asked.
Research matrix
Which question has stronger current support?
Research questionStronger current supportExplanation
Human evidenceTirzepatide
DSIP: Mixed and very limited human evidence. Tirzepatide: Mature human evidence.
Regulatory historyTirzepatide
DSIP: Not FDA approved; July 2026 PCAC voted narrowly against 503A listing. Tirzepatide: FDA approved for defined indications.
Mechanistic breadthDSIP
More named targets describes mechanistic breadth; it does not establish greater effectiveness.
Direct comparisonUnknown
Separate studies cannot establish comparative superiority.
Deeper when you want it
Explore the evidence and nuance
Best-studied areas and pathway mapSee shared targets, unique pathways, and the research questions attached to each record.
DSIP
- Chronic insomnia
- Sleep architecture and daytime performance
- Opioid and alcohol withdrawal
- Narcolepsy — single-case historical evidence
Tirzepatide
- Obesity
- Type 2 diabetes
- Cardiometabolic outcomes
Pathway and research map
Shared foundation and unique questions
Research confidence by questionCompare regulatory, human-evidence, outcome, and administration records side by side.
Question by question
What each evidence base can actually answer
Regulatory statusEvidence, not a winner
DSIPNot FDA approved; PCAC voted no
Not FDA approved. On July 24, 2026, PCAC reportedly voted 6-7 with one abstention against recommending emideltide for the 503A Bulks List; the vote is nonbinding and is not a drug-approval decision.
TirzepatideFDA-labeled indications
FDA approved as Mounjaro for type 2 diabetes and Zepbound for defined adult weight-management and OSA indications.
Evidence depthEvidence, not a winner
DSIPOld, tiny, conflicting studies
Several tiny controlled or externally controlled IV sleep studies, two uncontrolled opioid-withdrawal reports, one small anesthesia pharmacodynamic study, and broader preclinical mechanism research.
TirzepatideMature Phase 3
Multiple large Phase 3 trials, active-comparator studies, 176-week follow-up, a 13,299-participant cardiovascular outcomes trial, and newer 2026 maintenance data.
Weight outcomesEvidence, not a winner
DSIPNo controlled evidence
No controlled human evidence for weight loss, appetite control, body recomposition, or metabolic treatment was located.
TirzepatidePeer-reviewed Phase 3
SURMOUNT-1 peer-reviewed trial: mean change −15.0%, −19.5%, and −20.9% across studied doses versus −3.1% placebo at 72 weeks.
Type 2 diabetesEvidence, not a winner
DSIPNo controlled evidence
No controlled human diabetes or glycaemic-outcome program was located.
TirzepatideApproved + Phase 3
Extensive SURPASS program and FDA approval. SURPASS-2 directly compared tirzepatide with semaglutide 1 mg in type 2 diabetes.
Obstructive sleep apnoeaEvidence, not a winner
DSIPNo OSA evidence
No controlled human obstructive-sleep-apnoea outcome study was located. Chronic-insomnia findings cannot be transferred to OSA.
TirzepatideApproved + Phase 3
Two peer-reviewed Phase 3 trials support the FDA-approved Zepbound indication for moderate-to-severe OSA in adults with obesity.
Cardiovascular outcomesEvidence, not a winner
DSIPNo outcomes program
No cardiovascular outcomes program exists. A small anesthesia study found increased heart rate and reduced heart-rate variability acutely.
TirzepatideCVOT + HFpEF trial
SURPASS-CVOT found tirzepatide noninferior—but not superior—to dulaglutide for major cardiovascular events. In SUMMIT, a separate placebo-controlled HFpEF-and-obesity population had fewer composite cardiovascular-death or worsening-heart-failure events; that finding is population-specific.
Administration and handlingEvidence, not a winner
DSIPHistorical IV research only
Human research primarily used intravenous exposure. FDA found no effectiveness, pharmacokinetic, or safety data for the nominated subcutaneous route.
TirzepatideOfficial FDA label
FDA labels provide product-specific once-weekly subcutaneous dosing and handling. Approved presentations are solutions; no reconstitution is required.
Comparison limitationsUnderstand what this comparison cannot establish before interpreting separate studies.
Comparable evidence base
- No direct head-to-head trial is represented for this pair.
- Separate studies may use different populations, endpoints, durations, doses, routes, and estimands.
- Results should not be interpreted as comparative superiority or individual guidance.
Current unknowns
Questions the evidence cannot answer yet
- Whether any formulation or route provides reproducible sleep benefit and what formulation-specific pharmacokinetics, interactions, immunogenicity, abuse potential, and long-term safety look like.
- Long-term individual durability and rare events, plus evidence for uses outside studied and approved populations.
Community Intelligence
Emerging patterns, clearly separated from evidence
DSIP
No community experiences yetBe the first account holder to contribute.
Tirzepatide
No community experiences yetBe the first account holder to contribute.
Community Intelligence summarizes structured, self-reported experiences. It can reveal patterns and useful research questions, but it cannot prove safety, effectiveness, or cause and effect. Published evidence is always shown separately.